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Correlation between Proinflammatory Cytokines and Antiinflammatory 
Mediators and the Severity of Disease in Meningococcal Infections
Marcel van Deuren, Johanna van der Ven-Jongekrijg, Departments of Internal Medicine, Intensive Care and Medical
Anton K. M. Bartelink, Roelof van Dalen, Microbiology, University Hospital Nijmegen; Department o f Internal
Robert W. Sauerwein, and Jos W. M. van der Meer Medicine, Eemland Hospital, Amersfoort, Netherlands
Pro- and antiinflammatory cytokines and mediators were measured in 39 patients with acute life- 
threatening meningococcal infections classified into 3 groups: A, meningitis without shock (n -  20);
B, meningitis with shock (n = 9); and C, shock without meningitis (n = 10). The plasma concentra­
tions of proinflammatory endotoxin, tumor necrosis factor-a (TNF-a), interleukin (IL)-6, and IL- 
8 and antiinflammatory cytokines and mediators IL-1 receptor antagonist, IL-10, and soluble TNF 
receptors p55 and p75 were strongly associated with this classification; the highest concentrations 
were in group C. IL-4 was not measurable. IL-1/3 was increased only in rapidly fatal cases. In 
addition, cerebrospinal fluid (CSF) was analyzed in 21 patients for TNF-a and its soluble receptors.
In CSF, these compounds were mainly increased in group A, reflecting an intrathecal compartmen­
talized cytokine production. It is concluded that both pro- and antiinflammatory mediators are 
simultaneously increased and are strongly associated with a classification based on simple clinical 
parameters.
Acute infections with the gram-negative bacterium Neisseria 
meningitidis are characterized by an overwhelming course. 
Characteristically, within a few hours and up to a day, a child 
or young adult is struck down from full health to a perilous 
condition [1]. In its septic form, this infection clinically resem­
bles the experimental model in which endotoxin or lipopolysac- 
charide (LPS) is infused. After LPS infusion, serum concentra­
tions of so-called proinflammatory cytokines, such as tumor 
necrosis factor-a? (TNF-a), interleukin (IL)-l/?, IL-6, and IL-
8, sharply increase, and a septic shock-like state develops [2 - 
7]. The short peak of proinflammatory cytokines is directly 
followed by an increase of IL-1 receptor antagonist (IL-IRa), 
IL-10, and soluble TNF receptors (sTNFRs) [8-10]. These 
mediators are considered antiinflammatory because they reduce 
mortality in experimental endotoxemia [11-13].
In patients with meningococcal infections, serum concentra­
tions of the proinflammatory cytokines reportedly correlate 
with the degree of systemic involvement and severity of dis­
ease, and these cytokines are believed to play a pivotal role in 
the pathogenesis of meningococcal disease [14-17]. sTNFRs 
are also increased, and with a small series of patients, we 
reported high concentrations of the antiinflammatory IL-iRa 
[18, 19], As published recently, the antiinflammatory IL-10 
behaves similarly: high concentrations at admission in severely
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ill patients [20]. No data are available about the concentrations 
of IL-4 in meningococcal infections.
The principal aim of this study was to compare the concen­
trations of the above-mentioned pro- and antiinflammatory me­
diators in plasma and cerebrospinal fluid (CSF) in patients with 
life-threatening meningococcal infections with clinical findings 
and severity of disease.
ê
Materials and Methods
Patients. During November 1990 to June 1994, 45 patients 
with acute life-threatening bacteriologically proven meningococcal 
infections were admitted to the intensive care unit (ICU) of Univer­
sity Hospital Nijmegen (37 patients) or Eemland Hospital Amers­
foort (8). In all patients, diagnosis was verified by a positive culture 
of CSF, blood, or skin biopsy or by direct detection of gram- 
negative diplococci in a CSF or skin biopsy smear (or both) [21]. 
From 39 of these patients, a plasma or serum sample was available 
for endotoxin or cytokine (or both) measurements. Leukocytes in 
CSF were counted in all patients; in 21 patients, a CSF sample 
was available for cytokine measurement.
Patients were classified according to clinical findings and sever­
ity of systemic involvement [22]. Group A (n = 20) had meningitis 
without shock, group B (n = 9) had meningitis with shock, and 
group C {n = 10) had shock without meningitis. Meningitis was 
defined as >100 x 106 leukocytes/L in CSF. Shock was defined 
as a systolic blood pressure in the first hours after admission of 
<100 mm Hg in adults, <85 mm Hg in children 4-14 years old, 
and <75 mm Hg in children <4 years old [22-24]. Patients with 
shock were refractory to a fluid bolus and needed inotropic and 
vasoactive support, All patients received antibiotics immediately 
after admission; 33 patients were also treated with steroids. Four­
teen patients with shock underwent additional plasma exchange or 
whole blood exchange [25].
Table 1 summarizes the demographic characteristics and prog­
nostic parameters, such as duration of disease before first hospital
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Table 1. Characteristics of 39 patients with severe meningococcal infections.
Group A: Group B: Group C:
meningitis without meningitis and shock without
shock shock meningitis
No. of patients 20 9 10
No. female/no. male 11/9 5/4 2/8
Age, years 14.5 (2-64) 14 (0-21) 4* (1-18)
Disease period before first hospital admission, h 23 (11.5-84) 10.5t (3-30) 11.75* (2.75-16.5)
Leukocytes in cerebrospinal fluid, X 106/L 13,650 (3900-70,000) 417* (107-6000) 15 (1-98)
Peripheral leukocytes (at first hospital admission), X l09/L 20.9 (12.8-30.9) 1 1 .8* (2.8-26.8) 4.1* (2.0-13.6)
Bicarbonate (nadir within 12 h after first hospital admission), mmol/L 21.1 (15-28.4) 14.0* (11.5-21.2) 13.9* (2.9-18.3)
Platelets (nadir within 12 h after first hospital admission), X109/L 165 (51-388) 66* (42-325) 40* (11-155)
Fibrinogen (nadir within 12 h after first hospital admission), mg/L 5018 (3500-12,000) 2400* (230-4115) 1164* (90-3732)
No. of deaths (%) 2 ( 10) 1 ( 1 1 ) 4 (40)
NOTE. Data are median (range) unless stated otherwise. 
Significantly different vs. group A: P  =s *.005, t .05.
admission, the number of leukocytes in CSF and in peripheral 
blood, the bicarbonate concentration, the platelet count, and the 
fibrinogen concentration [23-27].
Blood sampling and cytokine measurements. Blood samples 
for cytokine assay were drawn at a median of 1 h (range, 0-9.5) 
after ICU admission. In patients treated with plasma or whole 
blood exchange, blood was drawn before the start of the first 
exchange session. Since most patients (n = 28) were referred by 
other hospitals, the delay between first hospital admission and first
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Figure 1. Plasma concentrations of endotoxin on admission to in­
tensive care unit in patients with meningitis (group A), meningitis 
with shock (group B), or shock without meningitis (group C). Patients 
who died are indicated with -h Horizontal lines indicate medians.
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blood sampling was a median of 4 h (range, 0-17). Consequently, 
most blood samples (37/39) were drawn after the start of antibiotic 
and steroid treatment.
Endotoxin level was determined in platelet-rich heparin plasma 
by a chromogenic limulus amebocyte lysate assay (KabiVitrum, 
Stockholm); the detection limit was 12.5 pg/mL [25]. Cytokines 
and sTNFRs were measured in aprotinin-containing platelet-poor 
EDTA plasma as described [19]. In some instances, when no 
EDTA plasma was available, citrate plasma or serum was used. 
Due to the limited amount of sample, in CSF only TNF-a and 
sTNFRs were measured.
TNF-a, IL-1/?, and IL-1 Ra were determined by RIA using poly­
clonal rabbit antibodies, according to methods of Granowitz et al.
[8], van der Meer et al. [28], and Lisi et al. [29] with some minor 
modifications. With these modifications, the lower detection limit 
decreased to 20 pg/mL for TNF-a and IL-1/?. TNF-a values in 
serum were reproducibly higher than values in plasma. Therefore, 
TNF-a data obtained in serum were corrected according to the 
following formula: plasma value = 0.584 X serum value + 19.5 
pg/mL (formula calculated from 128 paired serum and plasma 
samples [r = .958]).
The IL-IRa assay appeared to lack parallelism, so all samples 
were diluted at a fixed ratio (10 ¡iL of sample and 90 ¡iL of RIA 
buffer solution) that gave a detection range of 600-50,000 pg/ 
mL. IL-4 was measured by ELISA (Genzyme, Cambridge, MA). 
IL-6 was also measured by ELISA; this assay was not influenced 
by the presence of soluble IL-6 receptors [30], For measurement 
of IL-8, a sandwich EIA was used (Quantikine; R & D Systems, 
Minneapolis). IL-10 was measured by sandwich ELISA (Med- 
genix, Fleurus, Belgium).
sTNFRs p55 and p75 were measured by an enzyme-linked im- 
munobinding assay (ELIBA; Hoffmann-La Roche, Basel, Switzer­
land). Normal values (±SD) from 19 healthy volunteers were 1470 
± 190 and 2520 ± 660 pg/mL for sTNFR p55 and p75, respec­
tively. The TNF-a and sTNFR assays were not influenced by the 
addition of recombinant sTNFR (up to 10 ng/mL) or TNF-a (up 
to 2.5 ng/mL).
Statistical methods. The principal aim of the study was to 
relate the concentrations of the measured mediators in plasma or
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Table 2. Median plasma or serum concentrations of endotoxin, proinflammatory cytokines, and antiinflammatory cytokines and receptors on 
admission to the intensive care unit.
Mediator
No. o f  
evaluable 
patients
Group A: 
meningitis without shock
Group B: 
meningitis and shock
Group C: 
shock without meningitis
Endotoxin 27 <12.5 (<12 .5-220) 575* (90-3300) 1859* (162-530,000)
TNF-a 36 10 1  (60-182) 138 (75-220) 320** (102-1800)
IL-1/? 35 55 (25-110) 40* (3 0 -5 0 ) 1 10”  (30-2500)
IL-6 29 795 (46-2550) 5716' (341-287,500) 36,040*’ (3240-10.8  X 10*))
IL-8 19 52 (< 20-250) 2462* (325-3050) 6000* (5 7 7 -> 6 0 ,0 0 0 )
IL-IRa 35 5750 (635-12,000) 8500* (4400-24,250) 26,250** (6475—>50,000)
IL-10 33 32 (< 11-369) 869* (13-6177) 6396** (576-15,711)
sTNFR p55 39 4505 (2685-33,820) 13,390* (2630-28,490) 17,490* (6310-40,344)
sTNFR p75 39 10,798 (5500-32,080) 29,290* (12,220-59,140) 67,961** (21,175-94,756)
NOTE. Tumor necrosis factor-a (TNF~a), interleukin (IL), IL-1 receptor antagonist (IL-IRa), soluble TNF receptor (sTNFR), Data are pg/mL (range). 
Significantly different vs. group A: jP *.005, *.05.
Significantly different vs. group B; * P  .05.
CSF with the severity of disease as expressed by the classification 
system of Halstensen et al. [22]. Therefore, the study parameters 
were compared with the Kruskal-Wallis test. To allow for multiple 
comparisons, a Bonferroni correction was applied. Thus, P 
.0042 was considered significant. In this case, groups A-C were 
mutually compared using the Mann-Whitney U test. Spearman's 
rank correlation coefficient was calculated to quantify the correla­
tion between study parameters.
Results
Patient groups and outcome. All group A patients had a 
positive culture or Gram’s stain of CSF, whereas only 5 of 
them had meningococci demonstrated in skin biopsy or blood 
culture. In groups B and C, CSF examination showed meningo­
cocci in 17 of 19 patients; in these groups, skin biopsies or 
blood cultures were positive in 18 patients, indicating a more 
systemic involvement of the infection.
In total, 7 patients died. In group A, 2 patients died of 
cerebral herniation directly after admission. In group B, 1 pa­
tient died after 4 days when treatment was terminated because 
of severely mutilating distal gangrene and progressive meta­
bolic acidosis. In group C, 4 patients died from intractable 
shock within 16 h after admission. Among the 32 survivors, 4 
had serious sequelae. One group A patient had sensorineural 
deafness, 2 patients (1 each, groups B and C) needed plastic 
surgery for necrotic skin areas, and 1 group C patient had both 
legs amputated because of distal gangrene.
Concentrations o f cytokines. The plasma concentration of 
endotoxin was elevated in several samples and corresponded 
well with the classification of patients into groups (figure 1). 
Proinflammatory cytokines TNF-a, IL-1/?, IL-6, and IL-8 were 
also increased in several samples (table 2). Very high values 
were found in septic patients with fatal disease. In these pa­
tients, TNF-a was (median) 495 pg/mL (range, 165-1800), IL- 
1/3 was 145 pg/mL (range, 50-2500), IL-6 was 1.8 X 1G6 pg/
mL (range, 2.87 X 105—10.8 X  106), and IL-8 (measured in 
only 2 patients) was >33,000 pg/mL. In a group A patient 
dying of cerebral herniation, concentrations of these cytokines 
were only minimally increased. The levels of TNF-a, IL-8, 
and IL-6 reflected the degree of systemic involvement and 
severity of disease as expressed by the classification into groups 
A -C . IL-1/? showed a different pattern; it was increased only 
in rapidly fatal cases with septic shock. All 4 patients with 
shock and IL-1 ¡3 >115 pg/mL died within 16 h.
Antiinflammatory mediators IL-10, IL-IRa, and sTNFRs p55 
and p75 showed a similar pattern and also corresponded well 
with the categories (A -C ) of severity of disease (table 2, figure 
2). Circulating IL-4 was not detectable in any plasma sample.
As shown in table 3, the correlation between the plasma 
concentrations of the various proinflammatory and antiin­
flammatory mediators was very high (P .002), except for 
IL-1/?, which did not correlate at all with the other mediators.
The plasma concentration of TNF-o: in meningitis patients 
without shock (group A) was in the normal range (comparing 
values from controls). However, CSF concentrations of TNF-a 
and sTNFRs of these patients were definitely elevated; medians 
were TNF-a, 5585 pg/mL (range, 555 to >6000); sTNFR p55, 
6700 pg/mL (range, 4260-48,500); and sTNFR p75, 16,730 
pg/mL (range, 2165-94,680) (figure 3). These values differed 
significantly from those in group C: TNF-a, 160 pg/mL (range, 
<  160-600; P  =  .002); sTNFR p55, 4320 pg/mL (range, 1630- 
6440; P  = .016); and sTNFR p75, 1970 pg/mL (range, < 3 0 0 - 
5670; P  =  .001). Patients of group C who rapidly died tended 
to have higher CSF concentrations (figure 3C).
Discussion
In this study during the acute stage of meningococcal infec­
tion, circulating concentrations of both pro- and antiinflamma­
tory cytokines and mediators were increased and corresponded
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Figure 2. Plasma concentrations 
of antiinflammatory cytokines in­
terleukin (IL)-IO, IL-1 receptor an­
tagonist and soluble TNF receptors 
p55 and p75 on admission to inten­
sive care unit in patients with menin­
gitis (group A), meningitis with 
shock (group B), or shock without 
meningitis (group C). Patients who 
died are indicated with + . Hori­
zontal lines indicate medians.
with a clinical classification based on the degree of systemic 
involvement and severity of disease.
In 1987, Halstensen et al. [22] classified patients with menin­
gococcal infections into 4 subgroups: a, meningitis without 
hypotension; b5 septicemia with hypotension and meningitis; 
c, septicemia with hypotension but without meningitis; and d, 
septicemia without hypotension or meningitis. Outcome clearly 
differed among these groups, with mortality rates of 1.3%, 
7.4%, and 28.6% in groups a-c , respectively; all group d pa­
tients survived. More refined and complex prognostic scoring 
systems using laboratory data such as leukopenia, acidosis, and 
diffuse intravascular coagulation are also available (reviewed 
in [31]). The classification system of Halstensen et al. [22] is 
tightly coupled to these prognostic parameters (table 1). In 
addition, we have shown that the concentrations of endotoxin 
and proinflammatory cytokines TNF-a, IL-6, and IL-8 corre­
spond with this classification system, which confirms earlier 
findings [16, 17, 32, 33].
The pattern for IL-1/? was different. Similar to findings of 
Waage et al. [16], we found increased IL-1/? concentrations 
only in group C patients with a rapidly fatal course. Remark­
ably, the IL-1 /? concentration in patients with shock who sur­
vived (n = 12) was significantly lower than in survivors without
shock (P = .05). This observation may explain the conflicting 
data about the role of IL-1 /? in sepsis of different etiologies. 
Some studies report a positive correlation between IL-1 /? and 
the severity of disease, whereas others report the opposite [4, 
34, 35].
The exact role of IL-6 in the genesis of sepsis, having both 
pro- and antiinflammatory effects, has still to be established. 
In an experimental setting, IL-6 has been infused without lethal­
ity, and in vitro experiments have shown that IL-6 can inhibit 
TNF-a and IL-1/? production and stimulate IL-IRa production 
either directly or by IL-6-induced acute-phase proteins [36- 
38]. Yet, in clinical studies of patients with sepsis of different 
etiologies, IL-6 correlated well with the severity of disease 
[39]. Our results confirm this correlation for patients with me­
ningococcal infections, indicating that IL-6 is a good indicator 
of activation of the cytokine network.
IL-IRa and IL-10 are truly antiinflammatory cytokines. Both 
agents improve survival in experimental endotoxemia [11, 12]. 
IL-1 Ra blocks the proinflammatory action of IL-1 by competi­
tive binding to the IL-1 receptor [40]. IL-10 inhibits, as does 
IL-4, the production of TNF-a, IL-1/?, IL-6, and IL-8 and 
stimulates the production of IL-IRa [12, 41-44]. In our study, 
IL-1 Ra and IL-10 were produced at an early stage of meningo-
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Figure 3. Paired concentrations of tumor necrosis factor-a (TNF- 
a) and soluble TNF receptors (sTNFRs) p55 and p75 in cerebrospinal 
fluid and plasma from patients with meningitis (group A), meningitis 
with shock (group B), or shock without meningitis (group C). Patients 
who died are indicated with +.
coccal infections and the plasma concentrations corresponded
TNFRs also may be able to cap to e  TNF-a, inhibiting its bio­
logic effects. Thus, sTNFR may have antiinflammatory proper­
ties.
However, sTNFRs may also be pro inflammatory, since they 
increase the half-life of TNF-« and therefore prolong its action 
[46]. In sepsis and meningococcal infections, sTNFRs p55 and 
p75 are increased [13, IB, 19]. Gtrardin et al. [18] reported 
higher T N F-a-to -sT N F R  ratios in more severely ill patients 
and concluded that sTNFRs may detoxify TNF-a. The maximal 
sTNFR concentrations in our study were nearly identical to 
those of Girardin et al. (—50 ng/mL for p55 and 100 ng/mL 
for p75). This suggests that the human body contains a given 
number of TNFRs that can be shed on maximal stimulation. 
Consequently, during disease with very high TNF-o: plasma 
concentrations, the T N F -a-to -sT N F R  ratio will automatically 
increase.
The interpretation of sTNFR concentrations in patients with 
septic shock is even more difficult, since sTNFR is mainly 
cleared by the kidneys, and patients with shock and renal insuf­
ficiency will have higher sTNFR levels [47, 48]. In our study, 
TNF-a!“ to-sTN FR ratios did not differ significantly among 
groups A -C . In addition, 3 of 5 septic patients who died had 
low T N F-a-to-sT N FR  ratios. Overall, our results do not sup­
port a purely antiinflammatory role for endogenous sTNFR but 
rather suggest that sTNFR concentrations reflect preceding or 
ongoing TNF-a activity.
sTNFRs p55 and p75 differ with respect to their distribution 
on different cells [45]. In our study, the median ratio of plasma 
p75 to p55 in patients with meningitis (group A) was 2.27 
(range, 0.81-4.02), whereas in patients with shock without 
meningitis (group C), this was 3.18 (range, 2.19-6.24; P  — 
.018). For comparison, in 19 healthy volunteers, this ratio was 
1.67 (range, 1.23-2.18). The p75-to-p55 ratio in CSF also 
differed: 3.21 (range, 0.51-7.26) in group A and 0.46 (range, 
<0.18-0.88) in group C (P <  .001), This suggests either a 
disproportional release or differential clearance of these com­
pounds in both types of meningococcal infections.
Our observation of very high TNF-a concentrations in CSF 
of patients with meningitis without shock (group A) and con­
comitant low plasma concentrations is in line with that of 
lialstensen et al. [17], Brandtzaeg et al, [49], and Waage and 
colleagues [50, 51]. Those investigators reported on the com- 
partmentalization of cytokine production in meningococcal in­
fections. In our study, sTNFR showed a similar pattern of high 
concentration in CSF and low concentration in plasma in group 
A. Although the presence of TNF-a up to 2500 pg/mL did not 
influence the sTNFR assay, interaction at much higher levels 
of TNF-a (as observed in some CSF samples) cannot be totally
with the severity of disease, similar to the pattern observed for excluded. Remarkably, we also found increased TNF-a and
the proinflammatory cytokines.
The role of endogenous sTNFR during infections is complex. 
It is believed that sTNFR is released into the circulation after 
binding of TNF-a on the target cell. As such, this shedding 
may protect the cell against ongoing stimulation [45]. Shed
sTNFR concentrations in CSF of patients without meningitis 
who died rapidly of shock (group C). Possibly in these cases 
the increase in TNF-a and sTNFR in CSF is of a different 
origin, since it is known that a high systemic TNF-a or IL-1/3 
concentration can permeate the blood-brain barrier [52]. The
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Table 3, Spearman’s correlation coefficients between plasma concentrations of measured mediators 
(cytokines) on admission to the intensive care unit.
Endotoxin TNF-a IL-1/? IL-6 IL-8 IL-IRa IL-10 sTNFR p55 sTNFR p75
Endotoxin 1.00
TNF-a 0.71 1.00
IL-1/? -0.08 0.19 1.00
IL-6 0.86 0.79 0.07 L00
1L-8 0.91 0.81 0.00 0,75 1.00
IL-IRa 0.66 0.52 0.28 0.72 0.72 1.00
IL-10 0.71 0.66 0.09 0.71 0.85 0.80 1.00
sTNFR p 55 0.77 0.65 0.28 0.70 0.89 0.57 0.72 1.00
sTNFR p75 0.80 0.77 0.14 0.72 0.88 0.65 0.80 0.90 1.00
NOTE. Tumor necrosis factor-a (TNF-a), interleukin (IL), IL-1 receptor antagonist (IL-IRa), soluble TNF 
receptor (sTNFR).
different sTNFR p75-to-p55 ratios found in CSF of patients 
with (group A) and without (group C) meningitis may support 
this theory. Thus* cytokine production in meningococcal infec­
tions is compartmentalized but probably not completely segre­
gated, and mutual influences may complicate the final cytokine 
pattern.
In conclusion, in our patients with life-threatening meningo­
coccal infections, the degree of cytokine activation corres­
ponded well with a classification based on easily perceptible 
and simple clinical parameters. During the early stage of the 
disease both pro- and anti-inflammatory cytokines were in­
creased and probably represented a generalized activation of 
the cytokine network. This activation was compartmentalized 
but not segregated.
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